Description:
Vilanterol, also known as GW-642444, is a long-acting beta-2 agonist drug, which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).
- Molecular Weight:774.776
- Melting Point:126 - 127°C
- Purity:98%
Molecular Formula:
C24H33Cl2NO5.C20H16O2
Canonical SMILES:
O=C(O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.O[C@@H](CNCCCCCCOCCOCC4=C(Cl)C=CC=C4Cl)C5=CC=C(O)C(CO)=C5
InChI:
1S/C24H33Cl2NO5.C20H16O2/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28;21-19(22)20(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h5-9,14,24,27-30H,1-4,10-13,15-17H2;1-15H,(H,21,22)/t24-;/m0./s1
InChIKey:
KLOLZALDXGTNQE-JIDHJSLPSA-N
Solubility:
Soluble in DMSO.
Appearance:
Solid powder
Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Synonyms:
(R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol 2,2,2-triphenylacetate; GW-642444; GW642444; GW-642444; GW 642444X; Vilanterol; Vilanterol trifenatate More details are to be found
here